---
title: "Jiangsu Hengrui Pharmaceuticals Co.,Ltd (600276.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600276.SH.md"
symbol: "600276.SH"
name: "Jiangsu Hengrui Pharmaceuticals Co.,Ltd"
industry: "Pharmaceuticals"
datetime: "2026-05-19T14:05:01.254Z"
locales:
  - [en](https://longbridge.com/en/quote/600276.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600276.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600276.SH.md)
---

# Jiangsu Hengrui Pharmaceuticals Co.,Ltd (600276.SH)

## Company Overview

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.hengrui.com](https://www.hengrui.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:10.000Z

**Overall: B (0.26)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 3 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 11.55% |  |
| Net Profit YoY | 18.67% |  |
| P/B Ratio | 5.47 |  |
| Dividend Ratio | 0.37% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 347656090618.89 |  |
| Revenue | 32533274237.46 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 14.68% | A |
| Profit Margin | 24.93% | A |
| Gross Margin | 86.60% | A |
| Revenue YoY | 11.55% | B |
| Net Profit YoY | 18.67% | B |
| Total Assets YoY | 38.99% | A |
| Net Assets YoY | 34.91% | A |
| Cash Flow Margin | 141.23% | B |
| OCF YoY | 11.55% | B |
| Turnover | 0.53 | C |
| Gearing Ratio | 10.02% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Jiangsu Hengrui Pharmaceuticals Co.,Ltd",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "11.55%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "18.67%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "5.47",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.37%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "347656090618.89",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "32533274237.46",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "14.68%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "24.93%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "86.60%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "11.55%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "18.67%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "38.99%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "34.91%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "141.23%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "11.55%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.53",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "10.02%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 42.17 | 91/215 | 59.11 | 53.88 | 49.69 |
| PB | 5.38 | 195/215 | 7.85 | 7.05 | 6.25 |
| PS (TTM) | 10.51 | 187/215 | 14.15 | 12.94 | 11.86 |
| Dividend Yield | 0.37% | 141/215 | 0.36% | 0.33% | 0.30% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-17T16:00:00.000Z

Total Analysts: **23**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 16 | 70% |
| Overweight | 4 | 17% |
| Hold | 1 | 4% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 51.59 |
| Highest Target | 123.00 |
| Lowest Target | 66.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600276.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600276.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600276.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600276.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**